ClinicalTrials.gg
CompletedNCT01806311Updated Apr 20, 2025

Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg

A Phase 1 interventional study of Candesartan32mg and Amlodipine10mg in Hypertension, sponsored by HanAll BioPharma Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-20.

Sponsored by HanAll BioPharma Co., Ltd. (part of Daewoong Pharmaceutical Co. LTD.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. — 1 open to participants now, 3 under way, none of them phase 3. Hypertension · Daewoong Pharmaceutical Co. LTD..

Enrollment
9th of 10
36 · median 128
Started
2012
with 3 others
Phase 1
4 of 15
none open now
Registered
3rd of 15
by date

Among the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2012, is one of 4 in phase 1, and was the 3rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., or all of them as a file.
02

Study summary

Clinical trial to evalate the pharmacokinetic interactions and safety between single dose of amlodipine10mg and candesartan32mg and combiation dose amlodipine10mg with candesartan32mg in healthy male volunteers.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Pharmacokinetics
  • Safety
  • Male
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male, Age 20 to 45
  2. Subject must be willing and able to provide written to the study.

Exclusion criteria

Exclusion Criteria:

  1. History of any significant sickness, liver system, gall bladder system, kidney, nerve system, respiratory system, blood tumor, endocrine system, urinary system, mental disease, muscloskeletal system, immunity system, the ear, nose and throat system and cardiovascular system.
  2. History of any significant gastrointestinal system and surgery of gastrointestinal.
  3. History of any significant to amlodipine, candesartan, aspirin, antibiotic.
  4. Over 10 tobaccos a day.
  5. Other condition which in the opinion of the investigator preclude endrollment into the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    PartA: Candesartan, Candesartan + Amolodipine

    Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally

    Drug: Candesartan32mg · Drug: Amlodipine10mg

  • Active comparator
    PartB: Amlodipine, Amlodipine+Candesartan

    Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally

    Drug: Candesartan32mg · Drug: Amlodipine10mg

Interventions

  • DrugCandesartan32mg
  • DrugAmlodipine10mg
06

What researchers measure

Primary outcomes

  1. Part A : AUC, Cmax of Candesartan

    Time frame: Over a 24-hour sampling period

  2. Par B : AUC, Cmax of Amlodipine

    Time frame: Over a 24-hour sampling period

Secondary outcomes

  1. PartA: Cmin, tmax, CL/F of Candesartan

    Time frame: Over a 24-hour sampling period

  2. PartB: Cmin, tmax, CL/F of Amlodipine

    Time frame: Over a 24-hour sampling period

07

Study locations

1 site
  • Chungnam national university hospital,clinical trial center
    Daejeon, Chungcheongbul-do 301-721, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2013
First posted
Mar 7, 2013
Start
Dec 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Last update
Apr 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01806311
Responsible party
Sponsor
First posted
Mar 7, 2013
Start date
Dec 2012
Primary completion
Aug 2013
Completion
Aug 2013
Last update
Apr 20, 2025

Study contacts

Jang Hee Hong, Associate Professor
principal investigator · Chungnam national university hospital, Clinical trial center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion